Clinical trial · Interventional
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cesium-131 brachytherapy | Radiation | — | UNRESOLVED |
| Craniotomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Resection without brachytherapy
- description
- Patients will undergo craniotomy.
- interventionNames
- Procedure: Craniotomy
- type
- EXPERIMENTAL
- label
- Resection plus brachytherapy
- description
- Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist.
- interventionNames
- Procedure: Craniotomy
- Radiation: Cesium-131 brachytherapy
Primary outcomes (1)
- measure
- freedom from local progression
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients ≥ 18 years of age who are capable of giving consent * Undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease at the time of consent, and anticipated achievement of gross-total or near-total (\>/=95%) resection * Karnofsky Performance Status score (KPS) of ≥70 * Ability to undergo brain MRI with gadolinium Exclusion Criteria: * Unable to tolerate MRI or CT imaging * Pregnancy (patients must have a negative pregnancy test within 30 days of the operation) * Women must agree to not breastfeed for at least 12 weeks after the procedure (lactating and discarding in that interval allowable) * Diagnosis of leptomeningeal carcinomatosis or \>5 additional active or untreated CNS lesions for a total of \>6 active lesions * Prior irradiation (EQD2) in excess of 100 Gy to site of implant, using an α/β of 2 * Apposition of tumor margin to brainstem or optic apparatus * Previous infection within the operative field, current active systemic infection requiring systemic therapy, or immunodeficiency * Urgent surgery required prior to availability of brachytherapy Intraoperative Exclusion Criterion: * Patients will be excluded if intraoperative pathology is not consistent with \>/=5% viable metastatic disease.
References
Publications (0)
Data not yet available